Trials / Completed
CompletedNCT05381753
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
A National Multicenter, Noninterventional Clinical Study Evaluating the Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 61 (actual)
- Sponsor
- CStone Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an observational, multicenter, Real-word study to evaluate the safety and clinical efficacy of avapritinib in Chinese subjects with GIST.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avapritinib | Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed. |
| DRUG | Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al ) | Investigators will decide which TKI to use as well as the dosage, frequency, and duration. |
Timeline
- Start date
- 2022-08-29
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
- First posted
- 2022-05-19
- Last updated
- 2026-02-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05381753. Inclusion in this directory is not an endorsement.